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Over several decades, signiﬁcant advances have been made in
implementing several morphological and biochemical criteria to
deﬁne and characterize apoptosis. In order to appropriately
identify apoptosis in cellular cultures or in vivo (animal models),
with the ultimate aim of discovering novel, useful, speciﬁc, and
powerful pro-apoptotic antitumoral drugs, it is necessary to
accurately validate apoptotic processes through morphological,
biochemical, or immunological methods.
Often, apoptosis is detected and/or measured by only one
methodandtheauthorsfrequentlyuseimpreciseterminology,
such as ‘% apoptosis’, ‘% cell death’, instead of deﬁning the
speciﬁc method used such as ‘% cells with condensed
chromatin’, ‘% cells TUNEL positive’, ‘% cells Annexin V
positive’ and others.
1 The Nomenclature Committee on Cell
Death (NCCD) recommends and encourages researchers to
demonstrate that apoptosis or other forms of cell death take
place using more than one assay, as an artifact removal
feature, and to avoid the ‘confusing and imprecise’ nomen-
clature, such as ‘% apoptosis’, which ‘should deﬁnitively be
abandoned’.
1 Moreover, the NCCD ‘urges’ all life science
journals to join the Cell Death and Differentiation journal in
adopting these recommendations.
1
In order to determine the level of compliance with these
recommendations, we analyzed 110 Cancer Research
articles that detect/measure apoptosis, published between
August 15, 2010 and February 15, 2011, and 120 similar
research articles published in Cell Death & Disease between
January 1, 2010 and September 2011. In 21 of the Cancer
Research and 15 of the Cell Death & Disease articles,
apoptosis was determined by the authors for different
treatments or in different settings using a different combina-
tion of apoptosis techniques each time, thus leading the total
number of apoptotic determinations (entries) to 137 (Cancer
Research) and 136 (Cell Death & Disease) (see Table 1 and
Table 2). The results clearly show that in only 60 of the 137
entries(43.8%)forCancerResearchand96ofthe136entries
(70.58%) for Cell Death & Disease, the authors used at least
two different methods for apoptosis detection. In addition, we
determined that in 5 of the 137 (3.64%) entries from Cancer
Research and in 34 of the 136 (25%) of the entries from Cell
Death & Disease the authors use at least three methods for
apoptosis detection (Figure 1). Moreover, it is important to
emphasize that most, if not all of the apoptosis techniques
used to detect apoptosis as single methods may, as shown by
somereports,alsodetectnecrosisorothercellularprocesses.
As an example, DNA fragmentation measured by terminal
deoxynucleotidyl transferase (TdT)-mediated dUTP nick end
labeling (TUNEL) (26 of 137 from Cancer Research; 26 of 136
from Cell Death & Disease) or subG1 DNA content (30 of 137
from Cancer Research; 18 of 136 from Cell Death & Disease)
or Annexin V alone, without PI/7AAD (16 of 137 from Cancer
Research; 7 of 136 from Cell Death & Disease) and other
assays can also detect necrosis.
1–6 In addition, caspases can
be activated during cellular processes other than apoptosis.
1
Thus, more than one method for apoptosis detection should
be used.
In order to investigate the proper use of the speciﬁc name
for each method used, we analyzed the same entries
described above. Our analysis shows similar results for the
two journals. While for Cell Death & Disease, 83 from 136
entries(61.02%) usethe nameofthespeciﬁcmethodusedfor
apoptosis detection, among the 137 entries from Cancer
Research, 87 (63.5%) use the name of the speciﬁc method
used (Figure 1). These results certainly leave space for
improvement.
In conclusion, these results clearly suggest the need for
improvements and of adequate guidelines for authors,
reviewers, and editors regarding the apoptosis (in particular)
and cell death (in general) detection, and quantiﬁcation
methods.
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Use the speciﬁc name of the apoptosis
method (A)
87/137¼63.5% 36.5% of all entries use expressions such as ‘% apoptosis’, ‘% apoptotic cells’, ‘relative
apoptotic cells (fold change)’, ‘% death’ and others, instead of indicating the speciﬁc method
At least two methods for apoptosis
detection (B)
60/137¼43.8% Amongst 77/137 entries only one method is used: 26/79–caspase cleavage/activation; 3/79
only PARP cleavage; 31/79 DNA fragmentation/nuclear condensation; 15/79 TUNEL; 1/79
TUNEL and ELISA; 8/79 subG1; 2/79 subG1 and ELISA; 2/79 subG1 and Hoechst; 1/79
Hoechst; 1/79 Yo-Pro-1; 9/79 Annexin V only, 6/79 Annexin V with PI/7-AAD, 1/79 Citokeratin-





84/137¼61.13% 11/84 PARP cleavage only (without examining caspase activation)
DNA fragmentation/nuclear
condensation (2)
66/137¼48.17% 30/66 subG1; 26/66 TUNEL; 7/66 ELISA-nucleosomal fragmentation/release; 9/66 Hoechst
33342/33258, DAPI, Yo-Pro-1 (condensed/ fragmented chromatin)
Plasma membrane integrity/PS
exposure (3)
42/137¼30.65% 16/42 of entries examine Annexin V positive cells only (not combined with PI/7AAD)
Activation of pro-apoptotic Bcl-2 family
members (4)
1/137¼ 0.7% 1/6 shows Bax accumulation in the mitochondria; other 5/137 show only total levels of the pro/
anti-apoptotic members
Mitochondrial potential/integrity, release
of pro-apoptotic factors (5)
6/137¼4.38% 3/6 measure MMP and cyt c release together; 1/6 detect MMP only; 2/6 detect the Apo2.7 early
apoptotic marker
ROS detection (6) 4/137¼ 2.92% 4/4 DCFDA measurement of ROS
Other apoptotic features (blebbing/
ﬂoating cells etc) (7)
2/137¼1.45% 2/2 counting of ﬂoating cells (not speciﬁc for apoptosis)
No. of entries using methods (1) and (2) 32/137¼21.89% 15/30 subG1+activation/cleavage of caspases/ PARP (method 1); 10/30 TUNEL+method 1
No. of entries using methods (1) and (3) 24/137¼17.51% 21/24 Annexin V/PI(or 7-AAD)+method 1; 3/87 Annexin V only (without PI/7-AAD)+method 1
No. of entries using methods (2) and (3) 6/137¼4.38% 3/6 - subG1+Annexin V/with or without PI (or 7-AAD); 3/6 Hoechst/DAPI+Annexin V with/
without PI or 7-AAD)
No. of entries using at least three of the
considered methods
5/137¼3.65% Combinations of methods used: 1+2+3; 1+3+5; 1+3+6; 2+4+5+6; 1+2+5+7
Abbreviations: AAD, 7-amino-actinomycin D; Cyt c, cytochrome c; DAPI, 4, 6-diamidino-2-phenylindole; DCFDA, dichloroﬂuorescin diacetate; MMP, mitochondrial
membrane potential; PARP, poly(ADP ribose) polymerase 1; PI, propidium iodide; PS, phosphatidylserine; ROS, reactive oxygen species; TUNEL, terminal
deoxynucleotidyltransferase(TdT)-mediateddUTPnickendlabeling.Note:AhighernumberofarticleswerepublishedinCancerResearchbetweenAugust15,2010
and February 15, 2011; however, they measured other non-apoptotic cellular processes: non-apoptotic cell death and signaling, mitotic catastrophe, autophagy,
proliferation, metastasis, and others
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Use the speciﬁc name of the
apoptotic method (A)
83/136¼61.03% 38.97% of all entries use expressions such as ‘% apoptosis’, ‘% apoptotic cells’, ‘relative apoptotic cells
(fold change)’, ‘% death’ and others, instead of mentioning the speciﬁc method
At least two methods for apoptosis
detection (B)
96/136¼70.58% 40/136 entries use only one method for apoptosis detection: 14/40 caspases cleavage/activation; 1/40
only PARP cleavage detection; 12/40 DNA fragmentation/nuclear condensation (5/40 TUNEL; 3/40
subG1; 3/40 Hoechst; 1/40 nucleosomal fragmentation/release); 10/40 AnnexinV+/ PI/7AAD or




94/136¼69.11% 7/94–PARP cleavage detection only (without examining caspase activation/cleavage); 5/94 zVAD only
(without caspase activation/cleavage evaluation)
DNA fragmentation/nuclear
condensation (2)
71/136¼52.20% 26/71 TUNEL; 18/71 subG1; 15/71 Hoechst, 7/71 nucleosomal fragmentation/release, 4/71 DNA
ladder, 4/71 nuclear condensation/fragmentation (EM); 3/71 Acridine orange, 2/71 DAPI; 3/71
unspeciﬁed method (DNA fragmentation/condensation)
Plasma membrane integrity/PS
exposure (3)
57/136¼41.91% 52/57 Annexin V+/ PI or 7AAD (7/57 use Annexin V only); 2/57 PI/Yo-Pro-1; 2/57 Annexin V/To-Pro-3;
1/57 PI only
Activation of pro-apoptotic Bcl-2
family members (4)
7/136¼5.14% 7/7 measure Bax, Bak, or Bid activity, localization (Bax and Bak) or cleavage (Bid); other 14/137 entries




36/136¼26.47% 21/36 Cyt c release from mitochondria; 19/36 MMP; 4/36 measure both Cyt c release and MMP; 3/36
measure both Cyt c and Smac release
ROS detection (6) 14/136¼10.29% DFCDA and DHE measurements of ROS
Other apoptotic features
(blebbing/apoptotic bodies) (7)
5/136¼3.67% 3/5 cell blebbing; 2/5 apoptotic bodies
No. of entries using methods (1)
and (2)
45/136¼33.08% 19/45 TUNEL+activation/cleavage of caspases/ PARP (method 1); 10/45 subG1+method 1; 9/45
Hoechst+method 1
No. of entries using methods (1)
and (3)
32/136¼23.52% 28/32 AnnexinV+PI, 7-AAD or To-Pro-3+method 1; 3/87 Annexin V only (without PI/7-AAD)+method 1;
1/32 PI/Yo-Pro-1+method 1
No. of entries using methods (2)
and (3)
19/136¼13.97% 7/19 subG1+Annexin V with/without PI/7-AAD; 6/87 TUNEL+Annexin V with/without PI /7-AAD
No. of entries using at least three
of the considered methods
34/136¼25% Combinations of methods used: 5/34 (1+2+3+5; 1+2+5; 1+3+5); 3/5 (1+2+3; 1+4+5); 2/34 (1+2+7;
1+3+6; 1+3+5+6); 1/6 (1+2+6; 1+2+4; 1+5+6; 1+2+4+5; 1+3+5+6; 1+3+4+5; 1+2+4+5+6+7)
Abbreviations: AAD, 7-amino-actinomycin D; Cyt c, cytochrome c; DCFDA, dichloroﬂuorescin diacetate; DHE, dihydroethidium; EM, electron microscopy;
MMP, mitochondrial membrane potential; PARP, poly(ADP ribose) polymerase 1; PI, propidium iodide; PS, phosphatidylserine; ROS, reactive oxygen species.
Note: A higher number of articles were published in Cell Death & Disease between January 1, 2010 and September, 2011; however, they measured other
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Figure 1 Evaluation of the Cancer Research and Cell Death & Disease articles. (a) Percentage of entries using the speciﬁc name of the apoptosis method used (87 of
137¼63.5% for Cancer Research; 83 of 136¼61.03% for Cell Death & Disease), instead of using the general terms such as ‘% apoptosis’. (b) Percentage of entries using
one, two (55 of 137¼40.14% for Cancer Research; 62 of 136¼45.58% for Cell Death & Disease), or at least three methods (5 of 137¼3.65% for Cancer Research;3 4o f
136¼25% for Cell Death & Disease) for apoptosis detection/quantiﬁcation
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